• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Enzymatic Treatment of Organ Allografts to Universal Blood Type O

March 2, 2022

Organ transplant recipients with group O blood type often have to wait at least twice as long as group A, B or AB recipients and have a 20% greater risk of mortality while on the transplant waitlist.  Similar to RBCs, enzymatic removal of the terminal sugar epitope (α-galactose or N-acetyl-galactosamine) on A and B antigen oligosaccharides would convert these antigens to the universal group O blood type and expand the compatible organ donor pool.  Recently, two enzymes that remove the A antigen have been identified: FpGalNAc deacetylase and FpGalactoaminidase (Azymes).  Wang et al. show that Azymes removed more than 99% and 90% of the A antigen from RBC samples (n=5) and human aortae (n=3), respectively.  Furthermore, over 97% of endothelial A antigen was removed by Azymes during ex vivo lung perfusion over 4 hours (n=8).  Simulation of transplantation with incompatible lungs (treated with Azymes) using an ex vivo model suggest that this treatment may reduce antibody-mediated lung injury and rejection.  Further studies are needed to study antigen re-expression and long-term post-transplant effects of the lungs and other organs.

Reference:

Wang A, Ribeiro RVP, Ali A, Brambate E, et al.  Ex vivo enzymatic treatment converts blood type A donor lungs into universal blood type lungs.  Science Translational Medicine 2022; 14(632):  eabm7190. 

Filed Under

  • News
  • Serology/Genotyping

Recommended

  • FDA Guidance to Control for Bacterial Contamination in Platelets

  • Variation in Practice to Reduce Transfusion-Transmitted Cytomegalovirus

  • VIDEO: Red Cell Alloimmunization

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Directed Blood Donations Should be Limited

  • Babesia Infection Reduces Red Cell Deformability

  • New Erythropoietin Gene Variants Linked to Hereditary Erythrocytosis

  • Multifaceted Threats to the Blood Supply from Climate Change

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley